Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin (Q28365150)

Crossref

DOI

https://api.crossref.org/works/10.1136/BMJ.3.5770.343

30 April 2023

1 reference

1 reference

https://api.crossref.org/works/10.1136/BMJ.3.5770.343

30 April 2023

author name string

G. Poole

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A5314737

30 April 2023

P. Stradling

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A5314737

30 April 2023

S. Worlledge

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A5314737

full work available at URL

30 April 2023

language of work or name

English

0 references

publication date

7 August 1971

0 references

https://europepmc.org/articles/PMC1798649

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A5314737

https://europepmc.org/articles/PMC1798649?pdf=render

30 April 2023

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A5314737

https://syndication.highwire.org/content/doi/10.1136/bmj.3.5770.343

30 April 2023

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1136/BMJ.3.5770.343

30 April 2023

0 references

3

0 references

issue

5770

0 references

page(s)

343-7

0 references

cites work

Auto-immune hemolytic anemias.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798649

Twice-weekly streptomycin plus isoniazid for tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798649

Jaundice during treatment with rifampicin (12 cases)

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798649

Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798649

A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus pas

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798649

Intermittent Chemotherapy for Tuberculosis in an Urban Community

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798649

The long-term use of intermittent streptomycin plus isoniazid in the treatment of tuberculosis

27 November 2018

1 reference

12 December 2020

Coombs'-test positivity induced by drugs. Mechanisms of immunologic reactions and red cell destruction

1 reference

12 December 2020

Some comparative aspects of rifampicin and isoniazid

1 reference

12 December 2020

Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results

1 reference

12 December 2020

Rifampicin in treatment of experimental tuberculosis in mice

1 reference

12 December 2020

A cooperative study on rifampicin in original treatment of advanced pulmonary tuberculosis

1 reference

12 December 2020

Trial of sanatorium treatment including a comparison of standard and intermittent continuation chemotherapy: Central Bohemian Tuberculosis Services-WHO-British Medical Research Council investigation

1 reference

12 December 2020

Jaundice after rifampicin

1 reference

12 December 2020

Suitability of rifampicin for intermittent administration in the treatment of tuberculosis

1 reference

12 December 2020

Identifiers

DOI